Newscast – Page 2 – media

Simcere Pharmaceutical’s TL1A/IL-23p19 bispecific antibody goes global, partnering with Boehringer Ingelheim to expand the global inflammatory bowel disease market.

Recently , Simcere Pharmaceutical (2096.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Boehringer Ingelheim, a leading global pharmaceutical company, to jointly develop Simcere’s self-developed TL1A/IL-23p19 bispecific antibody SIM0709 for the treatment of inflammatory bowel disease. Under the agreement, Boehringer Ingelheim acquires global rights to the project outside of Greater China. Simcere Pharmaceutical will receive an upfront payment, plus payments of up to €1.058 billion based on success in development, registration, and commercial milestones, in addition to royalties from net sales outside of Greater China. More than 3 million people worldwide are affected by inflammatory bowel disease (IBD). This disease can accompany patients throughout their lives and progresses continuously, often leading to frequent hospitalizations and surgeries, and severely impacting quality of life. Current medical treatments cannot completely prevent or reverse the disease and its complications, resulting in a significant unmet clinical need ...
- Source: https://news.yaozh.com/archive/47027.html
- 61
- January 31, 2026
Within 29 days of its listing, Insilicon has secured four collaborations.

Recently , Insilicon announced a strategic collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, on drug development worth over HK$931 million . According to the agreement, the two parties will rely on Insilicon’s Pharma.AI platform to develop small molecule inhibitors for cardiovascular and metabolic diseases targeting specific targets. Insilicon will be responsible for the design and optimization of small molecule drugs, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization. It is understood that Insilicon was listed in Hong Kong on December 30, 2025, less than a month ago. This cooperation with Qilu Pharmaceutical is the fourth cooperation that has been implemented since its listing. 01 Reshaping the R&D Paradigm In the pharmaceutical industry, traditional new drug development is characterized by high investment, high risk, and long cycles. There is a saying in the industry that “the ‘double ten rule'” ...
- Source: drugdu
- 55
- January 31, 2026
Initial Clinical Exploration of D-0502 in Combination with ADC Therapies Officially Commenced.

[Shanghai Securities News / China Securities Journal] InventisBio released its latest institutional survey minutes on January 29. The company recently hosted representatives from various domestic and international institutional investors, including Harvest Fund, Bank of Shanghai Fund, UBS, and IKARIA. Discussions centered on the R&D progress of the company’s product pipeline. D-2570 Clinical Progress: InventisBio stated that D-2570 is currently in clinical development for immunological diseases such as psoriasis, ulcerative colitis (UC), psoriatic arthritis, and systemic lupus erythematosus (SLE). In December 2025, Phase II clinical data for D-2570 in treating moderate-to-severe plaque psoriasis demonstrated excellent efficacy, significantly outperforming the placebo group across all endpoints after 12 weeks. Notably, significant improvements in lesion severity and area were observed after only 4 weeks, indicating that D-2570 can rapidly alleviate disease burden. Garsorasib (D-1553) Updates: A randomized, controlled, double-blind, multicenter Phase III clinical trial is currently underway, comparing Garsorasib with docetaxel in patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who failed standard ...
- Source: https://finance.eastmoney.com/a/202601293635648485.html
- 59
- January 30, 2026
Pfizer’s blockbuster drug receives notice of approval!

According to the drug notification delivery information released by the NMPA (National Medical Products Administration) on January 27, 2026, Pfizer has received a notification regarding the supplemental New Drug Application (sNDA) for Talazoparib Tosylate Capsules. While the specific indication remains undisclosed, it is speculated to be for germline BRCA-mutated (gBRCAm) HER2-negative breast cancer. Talazoparib Tosylate Capsules (brand name: TALZENNA®) is an inhibitor of poly (ADP-ribose) polymerase (PARP, including PARP1 and PARP2) enzymes, which play a role in DNA repair. In October 2024, the NMPA approved TALZENNA® in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
- Source: drugdu
- 60
- January 30, 2026
Aminophylline tablets pass generic drug consistency evaluation

On January 29, Lisheng Pharmaceutical(002393) issued an announcement stating that recently, the company received a “Drug Supplement Application Approval Notice” from the National Medical Products Administration regarding the 0.1g specification of aminophylline tablets, with approval number 2026B00421. This drug has passed the consistency evaluation of generic drug quality and efficacy. The drug’s indications include bronchial asthma, wheezing bronchitis, and obstructive emphysema. 　　Passing the consistency evaluation will help enhance the drug’s market competitiveness. However, due to the nature of the pharmaceutical industry, the specific sales performance of various products may be affected by factors such as changes in the market environment, and therefore has considerable uncertainty. 　　In the first three quarters of 2025, Lisheng Pharmaceutical achieved revenue of RMB 1.007 billion and net profit attributable to the parent company of RMB 371 million.
- Source: https://finance.eastmoney.com/a/202601293635246476.html
- 56
- January 30, 2026
Propafenone Hydrochloride Injection Receives Drug Production Registration Certificate

On January 30th, Shijiazhuang Pharmaceutical Group announced on the Hong Kong Stock Exchange that it had obtained the drug production registration certificate from the National Medical Products Administration of China for propafenone hydrochloride injection (20ml:70mg). This drug is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation. Shijiazhuang Pharmaceutical Group is the third domestic company to receive this approval. Propafenone hydrochloride injection is mainly used for treating supraventricular tachycardia, such as atrioventricular junctional tachycardia, WPW syndrome complicated with supraventricular tachycardia or paroxysmal atrial fibrillation, and ventricular tachycardia requiring treatment or that may be fatal.
- Source: https://finance.eastmoney.com/a/202601303636739215.html
- 49
- January 30, 2026
Hengrui’s innovative drug camrelizumab in combination with apatinib mesylate and TACE for the treatment of liver cancer has been accepted for marketing authorization application

Recently, the National Medical Products Administration (NMPA) accepted the new indication marketing authorization applications for the innovative drugs Camrelizumab for Injection (AiRuiKa®) and Apatinib Mesylate (AiTan®) developed by Hengrui Medicine and its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. The indication is : Camrelizumab for Injection in combination with Apatinib Mesylate and transarterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma . Research on SHR-1210-III-336 This application for a new indication is based on a randomized, open-label, multicenter phase III clinical trial (SHR-1210-III-336) evaluating the efficacy and safety of camrelizumab and apatinib mesylate in combination with transarterial chemoembolization (TACE) versus TACE alone in patients with unresectable hepatocellular carcinoma. The study was led by Academician Jia Fan and Professor Shu-Kui Qin of Zhongshan Hospital affiliated with Fudan University, with participation from 34 centers nationwide, enrolling a total of 423 patients. The primary efficacy endpoint was progression-free survival (PFS) assessed by ...
- Source: https://bydrug.pharmcube.com/news/detail/e52478ede0711ec643afefcaf5bacc7a
- 53
- January 30, 2026
The world’s first clinically approved “autologous regenerated islets” for the treatment of type 2 diabetes! Ruipuchen Chuang opens a new dual-indication autologous regeneration track.

On January 29, the Investigational New Drug (IND) application for RGB-5088 pancreatic islet cell injection, independently developed by Hangzhou Ruipuchenchuang Technology Co., Ltd., for the treatment of type 2 diabetes was officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. This is the world’s first product to utilize autologous regenerated islet therapy to treat type 2 diabetes . “Autologous regenerated islet therapy” refers to the process of creating islet cells from the patient’s own cells to replace the patient’s dysfunctional islet cells, thereby achieving long-term stable control of blood sugar levels. The islet cells created by this product not only closely resemble adult islet cells in structure and function but also possess high glucose sensitivity, allowing them to regulate insulin secretion based on changes in blood glucose concentration. It is worth noting that RGB-5088 islet cell injection has previously been approved for clinical trials in type 1 diabetes. ...
- Source: https://mp.weixin.qq.com/s/EtUZYv7EphTZ59KW-Jh9Lw
- 57
- January 30, 2026
A new player enters the market for a blockbuster drug with sales exceeding 600 million yuan, marking the second half of the battle for trazodone tablets.

Recently, according to the NMPA (National Medical Products Administration) announcement, Zhejiang Jiangbei Pharmaceutical’s trazodone hydrochloride tablets have been approved for marketing, making it the 15th company to receive approval for this product. The addition of a new competitor to an established product reflects not just a simple accumulation of approvals, but rather a rapidly accelerating, crowded race in the field of psychotropic drugs. Trazodone hydrochloride tablets, an atypical antidepressant, belong to the phenylpiperazine and triazolidine derivative class and are second-generation antidepressants of the 5-HT2 antagonist and reuptake inhibitor (SARI) class. Developed by Angelini Pharma in Italy, trazodone hydrochloride tablets are both an effective antidepressant and a good sedative-hypnotic, especially suitable for depressed patients with anxiety or sleep disorders. It was first approved for marketing in Italy on October 15, 1971, and entered the Chinese market in 2000. The market competition for trazodone hydrochloride tablets is increasingly fierce. To date, more ...
- Source: https://news.yaozh.com/archive/47035.html
- 45
- January 30, 2026
FDA Issues Safety Alert for Radiofrequency Microneedling

The U.S. Food and Drug Administration (FDA) is warning consumers, patients and healthcare providers about the potential risk for serious complications from radiofrequency (RF) microneedling procedures. RF microneedling devices are commonly used to improve skin appearance of the face and neck — often referred to as “resurfacing,” “tightening” or “rejuvenation” to treat issues like wrinkles. The technology works by using an array of tiny needles (microneedles) to deliver RF energy and heat into the skin. This heat is intended to cause controlled changes in the tissue, promoting new collagen growth, according to the FDA. However, the FDA has received numerous reports of serious and potentially permanent injuries related to the microneedling procedure. The adverse events reported to the agency include: Severe burns Permanent scarring Fat loss (diminishing facial volume) Physical disfigurement Nerve damage These reported injuries have occasionally required follow-up ...
- Source: HealthDay
- 123
- November 5, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.